CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX): $1.37

0.04 (+3.05%)

POWR Rating

Component Grades








Add CTMX to Watchlist
Sign Up

CTMX Price/Volume Stats

Current price $1.37 52-week high $3.02
Prev. close $1.33 52-week low $1.04
Day low $1.37 Volume 98,398
Day high $1.43 Avg. volume 934,010
50-day MA $1.26 Dividend yield N/A
200-day MA $1.60 Market Cap 91.81M

CTMX Stock Price Chart Interactive Chart >


  • Growth is the dimension where CTMX ranks best; there it ranks ahead of 95.93% of US stocks.
  • The strongest trend for CTMX is in Quality, which has been heading down over the past 177 days.
  • CTMX's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).

CTMX Stock Summary

  • CYTOMX THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.88% of US listed stocks.
  • CTMX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.3% of US stocks.
  • With a year-over-year growth in debt of -29.61%, CYTOMX THERAPEUTICS INC's debt growth rate surpasses only 11.25% of about US stocks.
  • Stocks that are quantitatively similar to CTMX, based on their financial statements, market capitalization, and price volatility, are CRDF, HYLN, DBVT, VTGN, and PULM.
  • Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to

CTMX Valuation Summary

  • CTMX's EV/EBIT ratio is -0.7; this is 107.11% lower than that of the median Healthcare stock.
  • Over the past 98 months, CTMX's price/sales ratio has gone down 60.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2023-11-03 1.3 -1.0 -1.5 -0.7
CTMX 2023-11-02 1.2 -0.9 -1.4 -0.6
CTMX 2023-11-01 1.1 -0.8 -1.3 -0.5
CTMX 2023-10-31 1.1 -0.9 -1.3 -0.5
CTMX 2023-10-30 1.1 -0.9 -1.3 -0.5
CTMX 2023-10-27 1.1 -0.8 -1.3 -0.4

CTMX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at -14.07%.
  • Its 3 year revenue growth rate is now at -5.43%.
  • The 3 year net cashflow from operations growth rate now stands at -30.48%.
CTMX's revenue has moved up $5,523,000 over the prior 15 months.

The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 71.943 -140.586 -97.593
2022-06-30 72.615 -136.442 -96.881
2022-03-31 70.738 -130.404 -91.94
2021-12-31 69.573 -119.031 -83.609
2021-09-30 66.219 -105.266 -72.082
2021-06-30 66.42 -100.244 -64.208

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CytomX Therapeutics, Inc. (CTMX) Company Bio

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.

CTMX Latest News Stream

Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream

Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.

Yahoo | November 23, 2023

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down

The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.

Yahoo | November 22, 2023

Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | November 17, 2023

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | November 13, 2023

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2023 Financial Results. At this time, all participants are in a listen only-mode. After the speaker’s presentation there will be a question and answer session. [Operator Instructions] […]

Yahoo | November 8, 2023

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo 24.55%
3-mo -8.67%
6-mo -20.81%
1-year -21.26%
3-year -81.78%
5-year -90.07%
YTD -14.38%
2022 -63.05%
2021 -33.89%
2020 -21.18%
2019 -44.97%
2018 -28.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!